Gabapentin NDC 86211-112

NDC codes

FDA NDC Directory

Product NDC (as listed)86211-112Labeler and product segments. Claims need a package NDC.

Product NDC at billing width86211-0112Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
86211-112-01	86211011201	473 mL in 1 BOTTLE (86211-112-01)Marketed from Dec 15, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Gabapentin
Generic name (nonproprietary): gabapentin
Active ingredients: Gabapentin — 250 mg/5mL
Dosage form: Solution
Route: Oral
Labeler: JVET PHARMACEUTICALS LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 091286
Marketing start: Dec 15, 2025
Listing expires: Dec 31, 2026
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 86211-112_63a5fc6d-ca57-4726-b70d-805ac023d959SPL ID 63a5fc6d-ca57-4726-b70d-805ac023d959SPL set ID 63a5fc6d-ca57-4726-b70d-805ac023d959RxCUI 283523UNII 6CW7F3G59XUPC 0386211112016

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N486211011201 followed by a unit qualifier and the quantity

Package 86211-0112-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 10, 2025.

Indications (excerpt from the label)

Gabapentin oral solution is indicated for: • Management of postherpetic neuralgia in adults • Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy Gabapentin oral solution is indicated for: • Postherpetic neuralgia in adults • Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 091286

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 091286
Product	Strength	Form · route	Labeler	Product NDC
Gabapentin	Gabapentin 250 mg/5mL	SolutionOral	Ajenat Pharmaceuticals LLC	82983-423
Gabapentin	Gabapentin 250 mg/5mL	SolutionOral	Kesin Pharma Corporation	81033-123
Gabapentin	Gabapentin 50 mg/mL	SolutionOral	Kesin Pharma Corporation	81033-123
Gabapentin	Gabapentin 50 mg/mL	SolutionOral	Kesin Pharma Corporation	81033-124